

# Rheumatology Grand Rounds 2024 - Amyloidosis and Other Infiltrative Diseases in Rheumatology

October 11, 2024 – 9:00 AM

**Samuel Cook, DO:**

**Tucson**

## **Overall Activity Objectives:**

- 1 Diagnose patients with rheumatic and musculoskeletal diseases with improved accuracy
- 2 Utilize rheumatologic tests, imaging, procedures and interventions (i.e., non-pharmacologic, pharmacologic and surgical) with increased skill
- 3 Manage patients with rheumatic and musculoskeletal diseases with greater skill
- 4 Avoid and minimize adverse events for rheumatologic conditions and diseases
- 5 Utilize practice algorithms designed for our specific rheumatologic practice with greater frequency
- 6 Utilize clinical instruments to assess rheumatologic disease activity and functional outcomes

## **Session Objectives:**

- 1 Understand the pathophysiology of different amyloid subtypes.
- 2 Identify clinical features of amyloidosis.
- 3 Understand strategies for diagnosis and treatment of amyloidosis.
- 4 Compare and contrast other infiltrative diseases that may have rheumatologic manifestations.

## **Accreditation Statement:**

The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Relevant Financial Relationships Statement(s):**

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

<b>Name of individual</b>	<b>Individual's role in activity</b>	<b>Nature of Relationship(s) / Name of Ineligible Company(s)</b>
Kent Kwoh, MD	Activity Director	Consulting Fee-Express Scripts Membership on Advisory Committees or Review Panels, Board Membership, etc.-Kolon Tissue

		Gene Consulting Fee-GSK Consulting Fee-Xalud (Relationship has ended) Consulting Fee-Moebius Sun (Relationship has ended) Consulting Fee-Trial Spark Consulting Fee-Taiwan Liposome Compant Advisor-Apos Health - 09/23/2024
Samuel Cook, DO	Faculty	Nothing to disclose - 03/05/2024



THE UNIVERSITY OF ARIZONA  
**College of Medicine**  
Tucson